Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

A new study published in The Journal of Dermatology revealed that patients with palmoplantar pustulosis (PPP) who were 18 ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Patients with psoriasis had 1.68 times greater prevalence of onychomycosis than patients without psoriasis. The prevalence of onychomycosis is significantly higher among patients with psoriasis than ...

Johnson & Johnson (J&J) and Protagonist Therapeutics’s joint interleukin-23 (IL-23) inhibitor, icotrokinra, has met the primary endpoint in a Phase IIb study in patients with moderately to ...

US healthcare conglomerate Johnson & Johnson (NYSE: JNJ) appears to have a promising interleukin (IL)-23-blocking oral peptide on its hands in the shape of icotrokinra. In November of last year, J&J ...